welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
PTC Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients with Duchenne muscular dystrophy who are between 2- and 5-years-old. Duchenne is a rare childhood genetic disorder that causes progressive irreversible muscle deterioration and weakness. Emflaza was first approved by the FDA in February 2017 for the treatment of Duchenne in patients 5-years and older.
“We are excited to be able to bring Emflaza to younger boys living with Duchenne muscular dystrophy,” said Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. “The standard of care is to start Emflaza at the time of diagnosis. We believe that treating patients as young as possible, when they still have a substantial amount of muscle, will have the greatest benefit for patients that are two years and older.”

rareRelated
-
Intermittent PTH Treatment Improves Bone and Muscle in Glucocorticoid Treated Mdx Mice: A Model of Duchenne Muscular...Duchenne Muscular Dystrophy (DMD) is a p...
-
Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapyQuality of life in Duchenne Muscular Dys...
-
A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subj...To evaluate the efficacy and safety of p...
-
A Comparison of the Effects of Deflazacort and Prednisone Versus Placebo on Timed Functional Tests in Boys with Duch...Objective: To describe the timed motor ...
-
The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal SuppressionDuchenne muscular dystrophy (DMD or Duch...
-
Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRSObjective: To evaluate the effects of c...
-
Neurology care, diagnostics, and emerging therapies of the patient with Duchenne muscular dystrophyDuchenne muscular dystrophy is the most ...